Analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to post earnings per share (EPS) of ($0.46) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.50) to ($0.42). Iovance Biotherapeutics reported earnings per share of ($0.40) during the same quarter last year, which would indicate a negative year-over-year growth rate of 15%. The company is expected to issue its next quarterly earnings report on Monday, November 2nd.
According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.94) per share for the current financial year, with EPS estimates ranging from ($2.05) to ($1.79). For the next financial year, analysts expect that the business will post earnings of ($2.14) per share, with EPS estimates ranging from ($2.70) to ($1.69). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.05.
Large investors have recently added to or reduced their stakes in the company. Lindbrook Capital LLC bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth about $27,000. Citizens Financial Group Inc RI bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth about $27,000. Advisors Asset Management Inc. bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth about $80,000. US Bancorp DE lifted its holdings in shares of Iovance Biotherapeutics by 74.7% during the 1st quarter. US Bancorp DE now owns 3,688 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 1,577 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in Iovance Biotherapeutics during the 2nd quarter valued at about $110,000. 95.15% of the stock is owned by institutional investors.
NASDAQ:IOVA traded up $0.38 during midday trading on Tuesday, reaching $32.30. The stock had a trading volume of 25,617 shares, compared to its average volume of 1,731,123. Iovance Biotherapeutics has a 1-year low of $17.67 and a 1-year high of $41.49. The firm’s fifty day simple moving average is $31.26 and its 200-day simple moving average is $31.18. The stock has a market capitalization of $4.67 billion, a P/E ratio of -16.71 and a beta of 1.03.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.